anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis is a critical factor causing major mortality and morbidity in liver recipients.

* According to guidelines patients with active infection should be treated before listing, and those who develop infection while on the waiting list should be removed until the infection is cured or has improved with appropriate antimicrobial treatment.
* Live donor liver transplant (LDLT) in comparison to Deceased Donor Liver Transplant (DDLT) is a more planned surgery. This gives us an opportunity for preoperative optimization and surgery can be timed. In identifying the impact of timing of LDLT wrt. sepsis , major morbidity can be reduced by optimizing/delaying timing of transplant. On the other hand, preoperative optimization may not be as critical as currently thought, and many more patients , currently delisted following sepsis can reap the benefits of a timely transplant. Results will help in better selection of patients as well as better management of pre transplant sepsis. A variety of studies have evaluated the impact of preoperative sepsis at different periods prior to LT on postoperative outcomes but results are widely varied.

The subsets of macrophages in hepatic capsule are known as liver capsular macrophages(LCMs). LCMs recruit neutrophils in response to bacteria reaching the liver capsule .LCM depletion increases liver pathogen load. Further it is also important to study peritoneal macrophages in chronic liver disease . Chronic sterile inflammation, as in nonalcoholic fatty liver disease, is associated with constant release of damage-associated molecular patterns. Continuous activation and recruitment of peritoneal and Liver capsular macrophages may contribute to fibrogenesis under condition of chronic liver diseases. Study of LCMs and PMs could be a landmark study identifying peritoneal macrophages and Liver capsular macrophages as highly mobile cells with a specialized function , with many possible therapeutic applications.The study will be collecting data both prospectively and retrospectively and will involve assessment of association of timeline and profile of preoperative sepsis on mortality and morbidity of liver transplant recipients. Primary objective will be Correlation of timeline of sepsis with recipient outcome following Live donor liver transplant. Outcome parameters will be Post operative sepsis ,In hospital mortality, Hospital stay, ICU stay, Retransfer to ICU, Days on ventilator, Need for tracheostomy/re-intubation, Duration of inotropic support. Secondary objectives To study the impact of source of sepsis on postoperative outcomes, To evaluate the causative organism of sepsis on post operative outcome. To study the correlation between recipient liver capsular and peritoneal macrophage activity and preoperative sepsis timeline, profile as well as post operative recipient outcome. 25 samples will be collected for liver capsular and peritoneal macrophage study.
The present invention relates to a release liner which is suitable for a transdermal preparation and a method for manufacturing the same. The release liner which is suitable for a transdermal preparation of the present invention is attached to the adhesive-coating side of a medical patch for transdermal or mucosal absorption and expresses release performance. The release liner comprises: a polyethylene terephthalate film; and a silicone release coating layer on one side of the polyethylene terephthalate film, containing epoxy compounds and silane compounds. The film is characterized by satisfying formulas 1-3 (formula 1: 10 &le; RF &le; 50, formula 2: 100 &le; CA &le; 115, formula 3: TSi &le; 8.0). The release liner has superior release ability and shows print pitch stability because silicone residues are transferred on the back side of the release liner at a remarkably low transfer rate. Therefore, the release liner functions in a medical patch, especially a transdermal patch. A large amount of the release liners with uniform physical properties is provided by an in-line coating method and a simultaneous biaxially stretching method.
PURPOSE:To obtain a pack cosmetic, having a gentle change in temperature on the skin and capable of providing a comfortable warm feeling to the skin, excellent in persistence of exothermic temperature and good in promoting effects on blood circulation by blending a thermogenic substance coated with a specific coating agent with other ingredients. CONSTITUTION:A coating agent which is a semisolid to solid at ordinary temperature is selected from (A) an oil, e.g. a hydrocarbon, a wax, a hardened oil or a higher fatty acid, (B) a surfactant e.g. glycerol ester of a fatty acid, a polyoxyethylene alkyl ether or polyoxyethylene hardened castor oil, (C) a water- swellable film-forming agent, e.g. a polymer compound prepared by copolymerizing at least 1 to 3 kinds of alkylaminoethyl (meth)acrylates, alkyl (meth)acrylates and (meth)acrylic acid, and converting the resultant copolymer into an amphoteric substance with a halogenated acetic acid and (D) a hydrophobic film-forming agent, e.g. ethyl cellulose having >=1.5 substitution degree or vinyl acetate resin. The resultant coating agent is used to coat a thermogenic substance (e.g. magnesium sulfate, sodium carbonate or calcium chloride).
Saposin C was shown to be a trophic factor for a variety of cancer cells, e.g., prostate, lung, breast, and colon cancer cells. These cells expressed saposin C and responded to saposin C by increased levels of cell proliferation, cell migration, and cell invasion. Such activities typify and promote the neoplastic process. For prostate cancer, the androgen-insensitive prostate cancer cells responded to saposin C by higher levels of cell proliferation, cell migration and cell invasion than did the androgen-sensitive prostate cells. Stromal cells (from the prostate) were also responsive to saposin C-mediated signals in a manner typical of growth promoting compounds. The androgen-insensitive prostate cells were stimulated by saposin C to express higher levels of the urokinase plasminogen activator (uPA) and its receptor (uPAR), two proteins known to be involved in cell invasion. A conjugate of a peptide of the active region of saposin C (TX14A) and a toxin (saporin) was made and was shown to decrease the survival of prostate cancer cells, and the other cancer cells that were found to express saposin C (including cancers cells of the breast, colon, and lung). This conjugate or a compound of analogous action that inhibits cellular growth acting via a saposin-C binding receptor can be used to decrease tumor growth and/or treat disorders of stromal proliferation (e.g., benign prostatic hyperplasia, atherosclerosis, and vascular restenosis).
OBJECTIVES: The influence of advancing fibrosis on graft survival in the context of pediatric liver transplantation accentuates the critical role of protocol-driven liver biopsies, a practice adopted by numerous medical centers. Consequently, the exigency for noninvasive methodologies to assess graft fibrosis assumes heightened importance when conventional clinical and laboratory parameters fail to reveal signs of liver damage.
METHODS: This study aimed to assess the reliability of transient elastography (TE) in pediatric liver transplant recipients to detect graft fibrosis and compare the results of TE in patients who underwent biopsy.
RESULTS: This prospective cohort study included liver transplanted children who underwent biopsy at Ege University Children's Hospital between October 1, 2021, and October 31, 2022, and a healthy control group. According to TE, fibrosis was detected in 40 patients, and no fibrosis was detected in 50. The median time to develop fibrosis was 100 months (95% CI [83.1-116.8]). A statistically significant positive correlation existed between LSM and METAVIR fibrosis score (r = 0.562, p = 0.001). There was a statistically significant difference in LSM between patients with F2 fibrosis (7.8-8.8 kPa ± 3.2) compared to patients with F0 fibrosis (5.2 kPa ± 0.7) (p = 0.005) and F1 fibrosis (6.1 kPa ± 1.5) (p = 0.041), on ANOVA.
CONCLUSION: Liver allograft fibrosis is common in long-term follow-up in children who have undergone liver transplantation. Abnormal TE may guide physicians to consider liver biopsy to detect late allograft fibrosis in these children.
Previous studies have identified VETC as a new metastatic pattern independent of EMT that may be associated with immunosuppression as well as poor prognosis. Multiple retrospective studies find higher rates of postoperative recurrence, distant metastasis in VETC-positive patients. How to improve surgical prognosis in VETC-positive patients needs to be explored. There are no published studies on how to improve prognosis for this population. One of our unpublished retrospective studies found that VETC-positive patients receiving PD-1 monoclonal antibody was not effective in improving prognosis. However, PD-1 monoclonal antibody in combination with PD-1 monoclonal antibody effectively reduced postoperative recurrence and improved prognosis in VETC-positive patients. Based on our previous retrospective data, this multicenter prospective cohort study was designed to further validate and explore effective therapeutics.
Alopecia, while not life-threatening, significantly impacts mental health, identity, and self-esteem of those afflicted. Current pharmacological and surgical treatments often have side effects and are limited in their ability to regenerate hair follicles (HF). Therefore, effective solutions for alopecia remain elusive. We developed an innovative hair tonic capable of stimulating HF regeneration by harnessing abandoned electric energy generated during human activities, such as the frictional electric field from walking and the electric fields from electronic devices. We devised a convenient, non-volatile, and conductive hair tonic to capture these naturally occurring electric fields. We identified 6-pentyl-α-pyrone (6PP) from Trichoderma gamsii as an antifungal agent effective against the dandruff-associated fungus Malassezia that can influence alopecia and adopted it into our conductive bio-harvesting tonic (CBT). Testing on hair follicle dermal papilla cells (HFDPC) and SKH1 mice showed that CBT significantly enhanced HF proliferation and increased growth factors in vitro and in vivo. In SKH1 mice, application of CBT under electric stimulation visibly increased hair shaft length and follicle counts. Additionally, tests on actual human hair follicles demonstrated delayed hair follicle regression when electric stimulation and 6PP were applied. In conclusion, our innovative CBT offers a promising and convenient approach for improving hair growth and combating alopecia.
Metformin Hydrochloride Extended-release Tablets USP are oral antihyperglycemic drugs used in the management of type 2 diabetes. Metformin Hydrochloride (N,N-dimethylimidodicarbonimidic diamide Hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. The structural formula is as shown:

Metformin Hydrochloride is a white to off-white crystalline compound with a molecular formula of C4H11N5• HCl and a molecular weight of 165.63. Metformin Hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin Hydrochloride is 6.68.

Metformin Hydrochloride Extended-release Tablets USP contain 500 mg or 750 mg of Metformin Hydrochloride USP as the active ingredient.

Metformin Hydrochloride Extended-release Tablets USP 500 mg and 750 mg contain the inactive ingredients microcrystalline cellulose, hypromellose, povidone, sodium carboxymethyl cellulose, and magnesium stearate.

System Components and Performance-Metformin Hydrochloride Extended-release Tablets USP comprises a duel hydrophilic polymer matrix system. Metformin hydrochloride is combined with a drug release controlling polymers to form a monophasic matrix system. After administration, fluid from the gastrointestinal (GI) tract enters the tablet, causing the polymers to hydrate and swell. Drug is released slowly from the dosage form by a process of diffusion through the gel matrix that is essentially independent of pH. The hydrated polymer system is not rigid and is expected to be broken up by normal peristalsis in the GI tract. The biologically inert components of the tablet may occasionally remain intact during GI transit and will be eliminated in the feces as a soft, hydrated mass.

The USP Dissolution Test is pending.
This observational, cohort sub-study is embedded within a larger public health intervention that distributes at-home, self-administered, SARS-CoV-2 antigen testing kits to households within pre-selected communities through the CCPH. Within this sub-study, the investigators will evaluate the socio-behavioral mechanisms of SARS-CoV-2 community transmission, including social interactions, health behaviors, healthcare utilization, knowledge, disease burden, and feasibility of at-home testing. The central hypothesis is that focused community intervention will reduce COVID-19 transmission. The secondary hypothesis is that this intervention will increase vaccine uptake. Surveys and questionnaires will be completed by participants via a QR code from the test kits that directs participants to a link. Questionnaires will collect data on demographic characteristics, medical history and health status, COVID testing and symptoms, social interactions, knowledge of prevention strategies, infection risk, and attitudes towards vaccines.
Safety Data will be collected from participants who received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies in 6-month intervals up to 60 months after prime vaccination, including the duration in the participant's original study (Cohort 1). Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Safety Data for live born children to female participants will be followed up to 60 months after birth (Cohort 3).
BACKGROUND An exercise program was developed using risk factors for non-specific neck pain. This study aimed to compare the effects video-based versus image- and text-based remote home training performed using this exercise program in patients with non-specific neck pain. MATERIAL AND METHODS Among the 37 patients with non-specific neck pain recruited, 34 patients who satisfied the inclusion criteria were enrolled in this study. The participants were randomized into the experimental (n=17) and control (n=17) groups. The patients in the experimental group performed exercises using a video-based application system, whereas those in the control group performed exercises using an image- and text-based printout. In-home training was implemented for 6 weeks in both groups. The neck pain intensity, disability index, active range of motion (aROM), forward head posture (FHP), and compensatory neck flexion were measured before and after the intervention. The within-group and between-group differences were analyzed at the end of the interventions. RESULTS Improvements in pain intensity, cervical ROM, disability index, FHP, and compensatory neck flexion were observed after in-home training in the experimental group (P.05). Between-group comparison revealed that the experimental group exhibited greater improvement in pain intensity, cervical ROM, and FHP than the control group (P<.05). CONCLUSIONS The findings of this study suggest that the video-based home exercise program improved pain intensity, aROM, neck disability index, FHP, and compensatory neck flexion in patients with non-specific neck pain.
Two previous studies have demonstrated increased platelet aggregation 60 minutes after drinking a commercially available sugar-free energy drink. These studies utilized traditional platelet function studies, such as light transmission aggregometry (LTA), where platelet function is examined while adding varying concentrations of a panel of agonist to platelets. These studies are technically difficult, time intensive studies requiring specialized laboratories. They are relatively non-physiologic and do not mimic platelet response to vessel wall damage. Other tests better represent the reactions to vessel wall damage, including the PFA-100, which measures platelet aggregation and adhesion under conditions of high shear.

Overall, PFA-100 is less expensive, requires less technical skill, and is less time consuming than LTA. It has been utilized in bleeding disorders and is demonstrating promise as a marker of thrombophilia. PFA-100 has demonstrated sensitivity to drug and dietary effects. It has also shown differences in closure time between sedentary and athletic individuals PFA-100 has not been used to investigate the effect of energy drinks.
Patient in a semi-sitting position with the head tilted to the opposite side of the injection site. A linear US probe (4-12 MHz) will be placed parallel to the clavicle in the supraclavicular fossa, and the subclavian artery will be seen beating above the first rib.Then the probe will be moved cranially to identify the transverse process of the C7 vertebra at the level of the brachial plexus roots between the scalenus anterior and medius muscles.The needle will be inserted in a plane approach from lateral to medial to scalenus medius and C5-C6 brachial plexus roots. After negative aspiration, a total of 5 mL of bupivacaine 0.5% will be injected incrementally.
BACKGROUND: This study aimed to validate a previously published risk model (RM) which combines clinical and multiparametric MRI (mpMRI) parameters to predict extraprostatic extension (EPE) of prostate cancer (PC) prior to radical prostatectomy (RP).
MATERIALS AND METHODS: A previously published RM combining clinical with mpMRI parameters including European Society of Urogenital Radiology (ESUR) classification for EPE was retrospectively evaluated in a cohort of two urological university hospitals in Germany. Consecutive patients (n = 205, January 2015 -June 2021) with available preoperative MRI images, clinical information including PSA, prostate volume, ESUR classification for EPE, histopathological results of MRI-fusion biopsy and RP specimen were included. Validation was performed by receiver operating characteristic analysis and calibration plots. The RM's performance was compared to ESUR criteria.
RESULTS: Histopathological T3 stage was detected in 43% of the patients (n = 89); 45% at Essen and 42% at Düsseldorf. Discrimination performance between pT2 and pT3 of the RM in the entire cohort was AUC = 0.86 (AUC = 0.88 at site 1 and AUC = 0.85 at site 2). Calibration was good over the entire probability range. The discrimination performance of ESUR classification alone was comparable (AUC = 0.87).
CONCLUSIONS: The RM showed good discriminative performance to predict EPE for decision-making for RP as a patient-tailored risk stratification. However, when experienced MRI reading is available, standardized MRI reading with ESUR scoring is comparable regarding information outcome. A main limitation is the potentially limited transferability to other populations because of the high prevalence of EPE in our subgroups.
Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
The invention discloses an EGCG-containing oral pharmaceutical composition and its preparation method. The EGCG-containing oral pharmaceutical composition comprises EGCG, stevioside, citric acid and a medical auxiliary material. Weight ratio of EGCG to stevioside to citric acid is 30:9:1. The auxiliary material is maltodextrin. Dosage of the EGCG-containing oral pharmaceutical composition is 200-400 mg. The invention has the following beneficial effects: based on the EGCG's function of increasing immunity, the oral pharmaceutical composition containing the EGCG ingredient is development; during the preparation process, stevioside and citric acid are added such that taste of EGCG is effectively improved and EGCG is in a weakly acid environment and is not easy to oxidize; and by the oral dosage form, bioavailability of the EGCG is maximized and costs are effectively controlled.
This is a multicenter, retrospective and prospective, observational, no profit study including adult patients with LCH, diagnosed starting from January 2001 to two years after the first enrolled patient. Data from patients, diagnosed from January 2001 to the date of patient enrolment, is considered retrospective, while data collected after patient enrolment, and up to two years after the first enrolled patient, is considered prospective. At least one year of follow-up is expected for each patient. Each patient will be followed up to one year after the last enrolled patient. This study plans to collect clinical information at the time of diagnosis and at various follow-ups to evaluate the efficacy of first-line therapies. Diagnostic and therapeutic data will be collected from routine clinical evaluations and laboratory and instrumental investigations carried out during clinical practice. A sub-cohort of patients with available biological data on somatic mutations of the RAF-MEK-ERK genes will also be evaluated.
Administer UNITHROID tablets orally as a single daily dose, on an empty stomach, one-half to one hour before breakfast. 

Administer UNITHROID at least 4 hours before or after drugs that are known to interfere with UNITHROID absorption [see Drug Interactions (7.1)]. 

Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect UNITHROID absorption [see Drug Interactions (7.9), Clinical Pharmacology (12.3)]. 

Administer UNITHROID to infants and children who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 mL to 10 mL or 1 teaspoon to 2 teaspoons) of water and immediately administering the suspension by spoon or dropper. Do not store the suspension. Do not administer in foods that decrease absorption of UNITHROID, such as soybean-based infant formula [see Drug Interactions (7.9)].